Products
FIP1L1 antibody
- Product Name
- FIP1L1 antibody
- Catalogue No.
- FNab03131
- Size
- 100μg
- Form
- liquid
- Purification
- Immunogen affinity purified
- Purity
- ≥95% as determined by SDS-PAGE
- Clonality
- polyclonal
- Isotype
- IgG
- Storage
- PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20℃ for 12 months (Avoid repeated freeze / thaw cycles.)
Immunogen
- Immunogen
- FIP1 like 1
- Alternative Names
- FIP1 antibody, RHE antibody
- UniProt ID
- Q6UN15
- Observed MW
- 75 kDa
Application
- Tested Applications
- ELISA, WB, IHC, IF
- Recommended dilution
- WB: 1:500 - 1:2000; IHC: 1:50 - 1:200; IF: 1:50 - 1:100
Validated Images
K-562 cells were subjected to SDS PAGE followed by western blot with FNab03131(FIP1L1 antibody) at dilution of 1:1000
Immunohistochemistry of paraffin-embedded mouse liver using FNab03131(FIP1L1 antibody) at dilution of 1:50
- Background
- This gene encodes a subunit of the CPSF (cleavage and polyadenylation specificity factor) complex that polyadenylates the 3' end of mRNA precursors. This gene, the homolog of yeast Fip1 (factor interacting with PAP), binds to U-rich sequences of pre-mRNA and stimulates poly(A) polymerase activity. Its N-terminus contains a PAP-binding site and its C-terminus an RNA-binding domain. An interstitial chromosomal deletion on 4q12 creates an in-frame fusion of human genes FIP1L1 and PDGFRA (platelet-derived growth factor receptor, alpha). The FIP1L1-PDGFRA fusion gene encodes a constitutively activated tyrosine kinase that joins the first 233 amino acids of FIP1L1 to the last 523 amino acids of PDGFRA. This gene fusion and chromosomal deletion is the cause of some forms of idiopathic hypereosinophilic syndrome (HES). This syndrome, recently reclassified as chronic eosinophilic leukemia (CEL), is responsive to treatment with tyrosine kinase inhibitors. Alternative splicing results in multiple transcript variants encoding distinct isoforms.
